Watertown, Mass.-based pSivida Corp.'s eye inflammation treatment Durasert showed a significant reduction in inflammation recurrence rate at 12 months.
In a second phase 3 trial of 153 patients, 36.6% of Durasert-treated patients had a recurrence of posterior segment uveitis compared to 71.2% of patients in the sham group.
Posterior segment uveitis is a chronic, non-infectious inflammatory disease affecting the posterior segment of the eye, often involving the retina, and may lead to blindness.
Durasert, a three-year treatment for posterior segment uveitis, is a tiny micro-insert that is injected into the eye and delivers very small doses of a drug on a sustained basis.
PSivida previously reported that six months after treatment, only 21.8% of Durasert-treated patients saw a recurrence compared to 53.8% of patients in the sham group.
